| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 952 | 778 | 800 | 811 | 1,223 | 1,029 | 989 | 1,086 | 974 | 986 | 1,025 | 1,098 | 1,242 | 1,193 | 1,564 | 1,585 | 1,557 | 1,483 | 1,673 | 1,784 | 1,621 | 1,712 | 1,765 | 1,885 | 2,060 | 1,808 | 1,945 | 2,223 | 2,476 | 2,217 | 2,384 | 3,020 | 3,929 | 3,516 | 3,551 | 4,135 | 3,912 | 4,543 | 3,604 | 3,826 | 4,415 | 3,990 |
| Expenses | 653 | 606 | 727 | 615 | 740 | 719 | 706 | 762 | 738 | 735 | 786 | 836 | 937 | 886 | 982 | 1,160 | 1,137 | 1,029 | 1,174 | 1,307 | 1,247 | 1,284 | 1,363 | 1,459 | 1,476 | 1,427 | 1,515 | 1,733 | 1,911 | 1,783 | 1,894 | 2,624 | 2,820 | 2,741 | 2,769 | 3,051 | 3,013 | 2,813 | 2,905 | 3,070 | 3,339 | 3,193 |
| EBITDA | 300 | 172 | 73 | 196 | 483 | 309 | 283 | 324 | 236 | 250 | 239 | 262 | 306 | 307 | 582 | 425 | 420 | 454 | 499 | 477 | 373 | 428 | 402 | 427 | 584 | 380 | 430 | 489 | 565 | 434 | 490 | 396 | 1,109 | 775 | 782 | 1,084 | 900 | 1,730 | 699 | 756 | 1,077 | 797 |
| Operating Profit % | 21 % | 20 % | 6 % | 22 % | 21 % | 27 % | 25 % | 27 % | 20 % | 21 % | 19 % | 21 % | 20 % | 21 % | 26 % | 25 % | 26 % | 29 % | 25 % | 25 % | 20 % | 24 % | 22 % | 21 % | 20 % | 19 % | 18 % | 20 % | 21 % | 17 % | 18 % | 11 % | 25 % | 20 % | 18 % | 14 % | 22 % | 17 % | 18 % | 19 % | 23 % | 18 % |
| Depreciation | 59 | 59 | 61 | 64 | 65 | 66 | 68 | 70 | 73 | 99 | 94 | 97 | 95 | 99 | 112 | 117 | 120 | 124 | 132 | 144 | 152 | 167 | 178 | 186 | 184 | 195 | 202 | 206 | 212 | 218 | 231 | 301 | 364 | 358 | 389 | 415 | 407 | 405 | 420 | 425 | 436 | 455 |
| Interest | 0 | 4 | 3 | 2 | 21 | 6 | 7 | 9 | 5 | 16 | 14 | 15 | 17 | 18 | 19 | 19 | 16 | 17 | 14 | 18 | 17 | 13 | 7 | 5 | 34 | 20 | 23 | 15 | 11 | 20 | 30 | 120 | 249 | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 |
| Profit Before Tax | 249 | 165 | 20 | 141 | 409 | 238 | 208 | 245 | 159 | 135 | 132 | 150 | 193 | 190 | 451 | 289 | 284 | 313 | 354 | 315 | 204 | 249 | 218 | 236 | 366 | 166 | 206 | 269 | 343 | 197 | 229 | -26 | 497 | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 |
| Tax | 32 | 34 | 18 | 19 | 55 | 55 | 42 | 54 | 10 | 38 | 43 | 36 | 41 | 52 | 73 | 46 | 41 | 85 | 100 | 85 | 45 | 81 | 22 | 49 | 69 | 57 | 46 | 49 | 59 | 30 | 147 | -5 | 82 | 35 | 42 | 55 | 96 | 284 | 71 | 75 | 27 | 8 |
| Net Profit | 217 | 131 | 2 | 122 | 354 | 182 | 167 | 191 | 148 | 98 | 89 | 114 | 153 | 138 | 378 | 243 | 243 | 228 | 254 | 230 | 159 | 168 | 195 | 187 | 296 | 108 | 160 | 220 | 284 | 167 | 82 | -21 | 415 | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 |
| EPS in ₹ | 10.08 | 6.31 | -0.54 | 5.30 | 16.97 | 8.49 | 7.48 | 8.72 | 6.49 | 1.38 | 1.17 | 1.56 | 2.21 | 1.02 | 3.00 | 3.67 | 3.61 | 1.74 | 1.82 | 1.71 | 1.04 | 1.26 | 1.39 | 1.42 | 2.13 | 0.71 | 1.16 | 1.57 | 2.00 | 1.21 | 0.39 | -0.35 | 2.62 | 0.85 | 1.05 | 5.52 | 1.13 | 5.51 | -0.13 | 0.21 | 2.88 | 0.26 |
Biocon
Biocon
351.85
-12.35
(-3.39%)
Company has added their latest Presentation5 hours ago
Show All
Market Cap
47,041.07 Cr
EPS
8.46
PE Ratio
49.95
Dividend Yield
0.12 %
Industry
Healthcare52 Week High
406.00
52 Week Low
291.00
PB Ratio
1.86
Debt to Equity
0.84
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from16 analysts
Company News
View All News
Biocon reported strong demand in its Contract Research, Development and Manufacturing Organization (CRDMO) segment during its earnings call. The company indicated it has a stronger balance sheet following a Qualified Institutional Placement (QIP) and is targeting double-digit growth in its generics business.
Biocon Approves Solar Power Deal and Reports Mixed Quarterly Results16 hours ago
Biocon Limited's Board approved entering into agreements with Pro-zeal Green Power Sixteen Private Limited to purchase solar power and acquire a 26% stake for up to Rs. 1.40 crores. The company will maintain this stake throughout the power purchase agreement to maintain captive status under the Electricity Act. The solar power plant will have 3 MW capacity in Telangana. Additionally, Biocon reported quarterly results for the period ended June 30, 2025. On a standalone basis, the company posted a net loss of Rs. 83 million compared to a profit of Rs. 212 million in the previous quarter, with revenue from operations declining to Rs. 5,371 million from Rs. 6,438 million. However, consolidated results showed better performance with net profit of Rs. 4,594 million and total income of Rs. 44,539 million. The company's three business segments - Generics, Biosimilars, and CRDMO - reported mixed results with Generics segment showing losses while Biosimilars and CRDMO remained profitable.
Biocon Receives Approval for Pro-Zeal Green Power Deals, Plans 26% Stake Acquisition in PGPSPL16 hours ago
Biocon has received approval for deals with Pro-Zeal Green Power and plans to acquire a 26% stake in PGPSPL. The transactions involve green power arrangements, indicating the company's move into renewable energy partnerships.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,589.10 | #1 3,81,278.32 | 33.44 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 33.27 | |
6,015.50 | 1,59,692.62 | 70.60 | 9,712.00 | 18.67 | 2,191 | 26.74 | 28.01 | |
3,600.30 | 1,21,850.51 | 60.28 | 11,539.40 | 6.99 | 1,911 | 19.91 | 56.66 | |
1,490.00 | 1,20,348.47 | 22.34 | 28,409.50 | 7.12 | 5,291 | 9.88 | 45.58 | |
2,493.00 | 1,02,893.28 | 55.50 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 49.09 | |
1,207.10 | 1,00,741.08 | #1 17.64 | 33,741.20 | 16.73 | 5,725 | 1.26 | 33.53 | |
944.45 | 95,033.77 | 20.47 | 23,511.00 | 13.82 | 4,615 | -0.19 | 41.90 | |
1,927.20 | 88,014.35 | 24.03 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 52.40 | |
32,900.00 | 69,910.20 | 49.21 | 6,684.70 | 10.80 | 1,414 | 27.83 | 42.87 | |
1,053.10 | 61,164.22 | 18.48 | 31,378.10 | 17.55 | 3,366 | -10.24 | 36.16 |
Forecast
Actual
Growth Rate
Revenue Growth
5.43 %
Net Income Growth
10.14 %
Cash Flow Change
37.49 %
ROE
0.58 %
ROCE
1.95 %
EBITDA Margin (Avg.)
-0.38 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Fixed Assets | 1,630 | 1,749 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 | 31,963 |
| Current Assets | 2,563 | 3,971 | 4,048 | 4,149 | 4,889 | 5,325 | 7,600 | 8,382 | 12,334 | 15,179 | 16,286 |
| Capital Work in Progress | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 | 8,508 |
| Investments | 230 | 901 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 | 1,127 |
| Other Assets | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,311 | 7,406 | 8,127 | 13,189 | 16,434 | 17,199 |
| Total Liabilities | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Current Liabilities | 1,555 | 1,666 | 1,678 | 2,141 | 3,039 | 4,008 | 4,210 | 3,828 | 8,511 | 15,359 | 14,334 |
| Non Current Liabilities | 1,378 | 2,493 | 2,502 | 2,200 | 2,447 | 3,053 | 5,805 | 7,096 | 21,043 | 15,437 | 16,751 |
| Total Equity | 3,443 | 4,300 | 5,214 | 5,649 | 6,707 | 7,383 | 8,508 | 9,470 | 22,489 | 25,275 | 27,713 |
| Reserve & Surplus | 3,171 | 3,992 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 | 21,044 |
| Share Capital | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -94 | 300 | -47 | -261 | 210 | 165 | 72 | -243 | 641 | -380 | 2,004 |
| Investing Activities | -491 | -1,138 | -510 | -684 | -703 | -1,505 | -3,651 | -1,662 | -14,260 | -1,002 | -203 |
| Operating Activities | 211 | 371 | 640 | 662 | 1,155 | 1,283 | 1,160 | 1,177 | 1,853 | 2,954 | 4,061 |
| Financing Activities | 186 | 1,068 | -178 | -240 | -242 | 388 | 2,564 | 242 | 13,049 | -2,333 | -1,854 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 60.67 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 54.45 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 7.96 % | 6.55 % | 5.63 % | 5.90 % | 5.93 % | 5.66 % | 5.66 % | 6.04 % |
| DIIs | 6.65 % | 6.89 % | 6.87 % | 6.83 % | 7.79 % | 7.30 % | 7.76 % | 8.63 % | 11.90 % | 12.56 % | 14.08 % | 14.51 % | 13.68 % | 14.30 % | 14.44 % | 15.37 % | 15.72 % | 22.82 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 10.89 % | 11.03 % | 11.49 % | 11.37 % | 10.87 % | 10.72 % | 12.07 % | 12.46 % | 13.21 % | 13.34 % | 13.61 % | 14.47 % | 15.53 % | 14.63 % | 14.57 % | 14.07 % | 13.63 % | 12.58 % |
| Others | 21.79 % | 21.44 % | 21.00 % | 21.16 % | 20.70 % | 21.35 % | 19.54 % | 18.27 % | 14.26 % | 13.46 % | 3.70 % | 3.83 % | 4.52 % | 4.53 % | 4.42 % | 4.27 % | 4.34 % | 4.10 % |
| No of Share Holders | 0 | 3,11,349 | 3,38,815 | 3,63,447 | 3,64,502 | 3,47,911 | 3,41,016 | 3,69,816 | 4,11,086 | 4,12,441 | 4,15,046 | 4,34,339 | 4,70,261 | 4,43,513 | 4,39,503 | 4,27,705 | 4,24,297 | 4,30,217 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3 | 1 | 1 | 0.00 | 0.00 | 0.5 | 1.5 | 0.5 | 0.5 |
| Dividend Yield (%) | 0.00 | 1.01 | 0.33 | 0.37 | 0.00 | 0.00 | 0.25 | 0.57 | 0.15 | 0.14 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 08 Aug 2025 |  Annual General Meeting | NA | 08 Aug 2025 | 346.50 | 364.20 |
| 07 Aug 2025 |  Quarterly Result Announcement | NA | 07 Aug 2025 | 372.05 | 360.60 |
| 04 Jul 2025 |  Dividend | ₹ 0.50 /share | 04 Jul 2025 | 346.50 | 374.40 |
| 08 May 2025 | Quarterly Result Announcement | NA | 08 May 2025 | 339.10 | 346.50 |
| 30 Jan 2025 | Quarterly Result Announcement | NA | 30 Jan 2025 | 372.95 | 355.70 |
| 30 Oct 2024 | Quarterly Result Announcement | NA | 30 Oct 2024 | 370.65 | 326.85 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 311.90 | 339.20 |
| 05 Jul 2024 | Dividend | ₹ 0.50 /share | 05 Jul 2024 | 311.90 | 361.10 |
| 07 Jul 2023 | Dividend | ₹ 1.50 /share | 07 Jul 2023 | 240.45 | 259.50 |
| 01 Jul 2022 | Dividend | ₹ 0.50 /share | 30 Jun 2022 | 382.30 | 308.40 |
| 13 Jun 2019 |  Bonus | 1:1 | 12 Jun 2019 | 271.45 | 257.90 |
Announcements
Announcement under Regulation 30 (LODR)-Investor Presentation
5 hours ago
5 hours agoAnnouncement under Regulation 30 (LODR)-Monitoring Agency Report16 hours ago
16 hours agoAnnouncement under Regulation 30 (LODR)-Acquisition16 hours ago
16 hours agoOutcome Of Board Meeting - Acquisition16 hours ago
16 hours agoBoard Meeting Outcome for Financial Results For June 30 202516 hours ago
16 hours agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release17 hours ago
17 hours agoFinancial Results For The Quarter Ended June 30 202517 hours ago
17 hours agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 23, 2025
Jul 23, 2025Company StatementJul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 18, 2025
Jul 18, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 17, 2025
Jul 17, 2025Reg. 34 (1) Annual Report.Jul 17, 2025
Jul 17, 2025 47Th Annual General Meeting For Financial Year 2024-25 To Be Held On Friday August 08 2025Jul 17, 2025
Jul 17, 2025Press ReleaseJul 15, 2025
Jul 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Jul 10, 2025Certificate Pursuant To SEBI Master Circular No. SEBI/HO/DDHS/Pod1/P/CIR/2024/54
Dated May 22 2024.Jul 10, 2025
Jul 10, 2025Outcome Of Board Meeting - Appointment Of Interim Company Secretary And Compliance OfficerJul 09, 2025
Jul 09, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJul 09, 2025
Jul 09, 2025Board Meeting Outcome for Outcome Of Board Meeting - Appointment Of Interim Company Secretary And Compliance OfficerJul 09, 2025
Jul 09, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 08, 2025
Jul 08, 2025Board Meeting Intimation for Board Meeting Intimation To Approve And Take On Record The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025Jul 08, 2025
Jul 08, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 07, 2025
Jul 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 04, 2025
Jul 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 03, 2025
Jul 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 30, 2025
Jun 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 27, 2025
Jun 27, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Disclosure Under Regulation 30 Of The SEBI Listing RegulationsJun 26, 2025
Jun 26, 2025Board Meeting Outcome for Outcome Of Board MeetingJun 26, 2025
Jun 26, 2025Communication To The Shareholders W.R.T. TDS On Final DividendJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 24, 2025
Jun 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 20, 2025
Jun 20, 2025Announcement under Regulation 30 (LODR)-Qualified Institutional PlacementJun 20, 2025
Jun 20, 2025Qualified Institutions Placement - Approval And Adoption Of The Placement Document Dated June 19 2025Jun 19, 2025
Jun 19, 2025Qualified Institutions PlacementJun 19, 2025
Jun 19, 2025Credit RatingJun 18, 2025
Jun 18, 2025Qualified Institutions Placement Of Equity SharesJun 16, 2025
Jun 16, 2025Intimation Of The Approval Of The Audited Consolidated Financial Statements For The Financial Year March 31 2025Jun 16, 2025
Jun 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 09, 2025
Jun 09, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotJun 04, 2025
Jun 04, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJun 04, 2025
Jun 04, 2025Press ReleaseJun 02, 2025
Jun 02, 2025Reminder Letter To Holders Of Physical Securities For Furnishing Of KYC DetailsMay 27, 2025
May 27, 2025Company StatementMay 25, 2025
May 25, 2025Company StatementMay 22, 2025
May 22, 2025Company StatementMay 21, 2025
May 21, 2025Transcript Of Earnings Call Q4 FY25May 15, 2025
May 15, 2025Notification To Stock ExchangeMay 15, 2025
May 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2025
May 14, 2025Technical Indicators
RSI(14)
Neutral 40.84
ATR(14)
Less Volatile 10.93
STOCH(9,6)
Oversold 15.85
STOCH RSI(14)
Oversold 2.95
MACD(12,26)
Bearish -5.06
ADX(14)
Strong Trend 29.95
UO(9)
Bearish 39.01
ROC(12)
Downtrend And Accelerating -5.94
WillR(14)
Oversold -82.33
Mutual Fund Holdings
SBI Contra Direct Plan-Growth 
Kotak Large & Midcap Fund Direct-Growth 
ICICI Prudential Value Direct-Growth 
Nippon India Focused Fund Direct-Growth 
Franklin India Mid Cap Fund Direct-Growth 
HSBC Midcap Fund Direct-Growth 
Mirae Asset Large Cap Fund Direct- Growth 
Aditya Birla Sun Life Large Cap Direct Fund-Growth 
Invesco India Arbitrage Fund Direct-Growth About Biocon
Biocon Limited is India's largest fully-integrated biopharmaceutical company, focusing on biotechnology products and research services. Founded in 1978, Biocon specializes in treating diabetes, cancer, and autoimmune diseases. The company develops and commercializes novel biologics, biosimilars, complex small molecule APIs, and generic formulations for global markets. Biocon's product portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, and oncology treatments. The company operates manufacturing facilities in Bangalore, Hyderabad, and Visakhapatnam, utilizing various technology platforms such as microbial fermentation, chromatographic purification, chemical synthesis, and peptide synthesis. Biocon has expanded its global presence through strategic partnerships and has launched several biosimilar and generic products in international markets, including the United States, Europe, and emerging economies.
Listing Date
07 Apr, 2004(21 Years,
1 days)
Website
Chairperson NameKiran Mazumdar Shaw
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
